Publication date: 5th July 2021
While cancer mortality has declined significantly with the development of targeted therapies, genetic and functional differences among cells allow certain subpopulations to evade treatment. Such heterogeneity has been implicated in drug resistance, metastasis, and poor patient prognosis. Cellular senescence, a state of cell-cycle arrest, in tumor cells is a desirable therapeutic outcome and is linked to the expression of the enzyme β-galactosidase. Therefore, assessment of β-galactosidase activity in individual cells provides a measure of the therapeutic response with single-cell resolution. Herein, we report a microfluidic device designed to study enzyme activity in single cancer cells. The device accomplishes selective capture of cancer cells by dielectrophoresis (DEP) at an array of wireless bipolar electrodes (BPEs). Following capture, cells are transferred into picoliter-scale reaction chambers. At a second capture point, inside the chambers, the cells are held in place during the introduction of reagents for the enzymatic assay. The chambers are subsequently isolated with an immiscible phase – a conductive, hydrophobic ionic liquid. Finally, the cells are electrically lysed to release intracellular β-galactosidase, which cleaves a fluorogenic substrate. Single-cell enzymatic activity is evaluated by following the accumulation of the fluorescent product over time. Our results demonstrate that cancer cells can be selectively captured, isolated and lysed with a high efficiency that is independent of chamber diameter – making this feature of the device tunable. We further report the distribution of β-galactosidase activity in a breast adenocarcinoma cell line (MDA-MB-231) and confirm that the population average β-galactosidase activity for individual cells assayed in parallel aligns with that obtained for ensemble measurements.